WO2017106568A1 - Combinaison d'un inhibiteur de jak et d'un inhibiteur de bromodomaine pour le traitement de cancers - Google Patents

Combinaison d'un inhibiteur de jak et d'un inhibiteur de bromodomaine pour le traitement de cancers Download PDF

Info

Publication number
WO2017106568A1
WO2017106568A1 PCT/US2016/067039 US2016067039W WO2017106568A1 WO 2017106568 A1 WO2017106568 A1 WO 2017106568A1 US 2016067039 W US2016067039 W US 2016067039W WO 2017106568 A1 WO2017106568 A1 WO 2017106568A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
acceptable salt
alkyl
aryl
heteroaryl
Prior art date
Application number
PCT/US2016/067039
Other languages
English (en)
Inventor
Jamie Geier BATES
Daniel B. Tumas
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of WO2017106568A1 publication Critical patent/WO2017106568A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • Janus kinase is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway.
  • Filgotinib is a JAKl selective inhibitor.
  • BET (Bromodomain and Extra-Terminal motif) inhibitors are a class of drugs with anticancer, immunosuppressive, and other effects. They reversibly bind the BET proteins BRD2, BRD3, BRD4 and BRDT, and prevent protein-protein interactions between BET proteins and acetylated histones and transcription factors.
  • Described herein are methods of treating cancers comprising administering filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, and a BET inhibitor, to a patient in need thereof.
  • provided herein is a method of treating cancer in a human in need thereof, comprising administering to the human:
  • the BET inhibitor is a compound of the formula: wherein: one ⁇ is a single bond and the other— is a double bond;
  • R la and R lb are each independently Ci_ 6 alkyl optionally substituted with from 1 to 5 R 20 groups; R 2a and R 2b are each independently H or halo;
  • R 3 is -B(OH) 2 , -B(OR a ) 2 , halo, -C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a ,
  • R 5 is -C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a , or -S(0) 2 NR a R b , H, CM O alkyl, CM O haloalkyl, CM O alkoxy, amino, Cs_io aryl, C 6 -2o arylalkyl, CM O heteroalkyl, Cs_io heteroaryl, or
  • each of CM O alkyl, CM O haloalkyl, CM O alkoxy, amino, C5-10 aryl, C 6 -20 arylalkyl, CM O heteroalkyl, Cs_io heteroaryl, and C 6 -2o heteroarylalkyl is optionally substituted with from 1 to 5 R 20 groups;
  • each R a and R b is independently selected from the group consisting of H, C M O alkyl, C5-10 aryl, C 6 -20 arylalkyl, CM O heteroalkyl, C5-10 heteroaryl, and C 6 -20 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R 20 groups;
  • each R 20 is independently selected from the group consisting of acyl, CM O alkyl, CM O alkoxy, amino, amido, amidino, C5-10 aryl, C 6 -20 arylalkyl, azido, carbamo
  • this disclosure provides a method for treating cancer in a human in need thereof, comprising administering to the human:
  • this disclosure provides a co-formulation comprising:
  • this disclosure provides a composition for use in the treatment of caner, the composition comprising: filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof; and a BET inhibitor.
  • the compound names provided herein are named using ChemBioDraw Ultra 12.0.
  • One skilled in the art understands that the compound may be named or identified using various commonly recognized nomenclature systems and symbols.
  • the compound may be named or identified with common names, systematic or non- systematic names.
  • the nomenclature systems and symbols that are commonly recognized in the art of chemistry include, for example, Chemical Abstract Service (CAS), ChemBioDraw Ultra, and International Union of Pure and Applied Chemistry (IUPAC).
  • Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as, but not limited to 2 H (deuterium, D), 3 H (tritium), n C, 13 C, 14 C, 15 N, 18 F, 31 P, 32 P, 35 S, 36 C1 and
  • isotopically labeled compounds of the present disclosure for example those into which radioactive isotopes such as 3 H, 13 C and 14 C are incorporated, are provided.
  • Such isotopically labeled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of subjects (e.g. humans).
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • any pharmaceutically acceptable salts, or hydrates as the case may be.
  • the compounds disclosed herein may be varied such that from 1 to n hydrogens attached to a carbon atom is/are replaced by deuterium, in which n is the number of hydrogens in the molecule.
  • Such compounds may exhibit increased resistance to metabolism and are thus useful for increasing the half life of the compound when administered to a mammal. See, for example, Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol. Sci. 5(12):524-527 (1984).
  • Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.
  • Deuterium labeled or substituted therapeutic compounds of the disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to absorption, distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements and/or an improvement in therapeutic index.
  • An 18 F labeled compound may be useful for PET or SPECT studies.
  • Isotopically labeled compounds of this disclosure can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. It is understood that deuterium in this context is regarded as a substituent in the compounds provided herein.
  • the concentration of such a heavier isotope, specifically deuterium may be defined by an isotopic enrichment factor.
  • any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom.
  • a position is designated specifically as "H” or "hydrogen”
  • the position is understood to have hydrogen at its natural abundance isotopic composition.
  • any atom specifically designated as a deuterium (D) is meant to represent deuterium.
  • a dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning.
  • a wavy line drawn through a line in a structure indicates a point of attachment of a group.
  • a dashed line indicates an optional bond.
  • no directionality is indicated or implied by the order in which a chemical group is written.
  • the group "-SO 2 CH 2 -” is equivalent to "-CH 2 SO 2 -” and both may be connected in either direction.
  • the prefix "C u _ v " indicates that the following group has from u to v carbon atoms, one or more of which, in certain groups (e.g. heteroalkyl, heteroaryl, heteroarylalkyl, etc.), may be replaced with one or more heteroatoms or heteroatomic groups.
  • C 1-6 alkyl indicates that the alkyl group has from 1 to 6 carbon atoms.
  • certain commonly used alternative chemical names may or may not be used.
  • a divalent group such as a divalent "alkyl” group, a divalent “aryl” group, etc., may also be referred to as an "alkylene” group or an "alkylenyl” group, an "arylene” group or an “arylenyl” group, respectively.
  • Alkyl refers to any aliphatic hydrocarbon group, i.e. any linear, branched, cyclic, or spiro nonaromatic hydrocarbon group or an isomer or combination thereof.
  • alkyl includes terms used in the art to describe saturated and unsaturated aliphatic hydrocarbon groups with one or more points of attachment, including alkenyl (an aliphatic group containing at least one carbon-carbon double bond), alkylene (a divalent aliphatic group), alkynyl (an aliphatic group containing at least one carbon-carbon triple bond), cycloalkyl (a cyclic aliphatic group), alkylcycloalkyl (a linear or branched aliphatic group attached to a cyclic aliphatic group), and the like.
  • Alkyl groups include, but are not limited to, methyl; ethyl; propyls such as propan-l-yl, propan-2-yl (iso-propyl), and cyclopropyls such as cyclopropan-l-yl, etc.; butyls such as butan-l-yl, butan-2-yl (sec-butyl), 2-methyl-propan-l-yl (iso-butyl), 2-methyl- propan-2-yl (t-butyl), cyclobutan-l-yl; butenes (e.g. (E)-but-2-ene, (Z)-but-2-ene); pentyls;
  • propyls such as propan-l-yl, propan-2-yl (iso-propyl), and cyclopropyls such as cyclopropan-l-yl, etc.
  • butyls such as butan-l-yl, butan-2-y
  • alkyl group comprises from 1 to about 10 carbon atoms, e.g., from 1 to 6 carbon atoms.
  • alkyl is a monovalent, linear or branched, saturated aliphatic hydrocarbon group comprising from 1 to about 10 carbon atoms, e.g., from 1 to 6 carbon atoms.
  • Alkenyl groups include ethenyl, propenyl, 1,3-butadienyl, and the like.
  • Alkynyl may have from 2 to about 10 carbon atoms, e.g. from 2 to 6 carbon atoms or 2 to 4 carbon atoms.
  • Alkynyl is a subset of “alkyl” and refers to an aliphatic group containing at least one carbon-carbon triple bond.
  • alkynyl is also meant to include those groups having one triple bond and one double bond.
  • Alkoxy refers to the group -O-alkyl, wherein the alkyl group may be optionally substituted. Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, sec-butoxy, and n-pentoxy.
  • cycloheteroalkyl aryl, arylalkyl, heteroalkyl, heteroaryl or heteroarylalkyl as defined herein, each of which may be optionally substituted, as defined herein.
  • Representative examples include, but are not limited to formyl, acetyl, cylcohexylcarbonyl, cyclohexylmethyl-carbonyl, benzoyl, benzyloxycarbonyl and the like.
  • heterocyclo alkyl refers to the group -NRyRz wherein Ry and Rz are independently selected from the group consisting of hydrogen, alkyl, aryl, heteralkyl, heteroaryl (each of which may be optionally substituted), and where Ry and Rz are optionally joined together with the nitrogen bound thereto to form a heterocycloalkyl or heteroaryl heteroaryl (each of which may be optionally substituted).
  • Aryl refers to a group with one or more aromatic rings. It may be a single aromatic ring or multiple aromatic rings which are fused together, linked covalently, or linked via one or more such as a methylene or ethylene moiety.
  • Aryl groups include, but are not limited to, those groups derived from acenaphthylene, anthracene, azulene, benzene, biphenyl, chrysene,
  • aryl group comprises from 5 to about 20 carbon atoms, e.g., from 5 to 20 carbon atoms, e.g. from 5 to 10 carbon atoms. In some embodiments, aryl is a a single aromatic ring or multiple aromatic rings which are fused together.
  • Arylalkyl refers to an aryl group attached to an alkyl group.
  • Arylalkyl groups include, but are not limited to, benzyl, tolyl, dimethylphenyl, 2-phenylethan-l-yl, 2- naphthylmethyl, 2-naphthylethan-l-yl, naphthobenzyl, phenylvinyl, diphenylmethyl, and the like.
  • the "arylalkyl” may be attached to the rest of the compound of formula (I) through the aryl group.
  • the "arylalkyl” may be attached to the rest of the compound of formula (I) through the alkyl group.
  • arylalkyl group comprises from 6 to about 30 carbon atoms, e.g. the alkyl portion of the arylalkyl group can comprise from 1 to about 10 carbon atoms and the aryl portion of the arylalkyl group can comprise from 5 to about 20 carbon atoms.
  • an arylalkyl group comprises from 6 to about 20 carbon atoms, e.g. the alkyl portion of the arylalkyl group can comprise from 1 to about 10 carbon atoms and the aryl portion of the arylalkyl group can comprise from 5 to about 10 carbon atoms.
  • Aryloxy refers to the group -O-aryl, including by way of example, phenoxy and naphthoxy.
  • Bosonic acid refers to the group -B(OH) 2 .
  • Bosenonic acid ester refers to an ester derivative of a boronic acid compound. Suitable boronic acid ester derivatives include those of the formula -B(OR) 2 where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl, each of which may be optionally substituted.
  • boronic acid ester may be pinacol ester or catechol ester.
  • Carbamoyl refers to the group -C(0)NR y R z where R y and R z are defined as in “amino" above.
  • Carboxyl or “carboxy” refers to -COOH or salts thereof.
  • Carboxyl ester or “carboxy ester” refers to the groups -C(0)OR, wherein R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl, each of which may be optionally substituted. In one embodiment, R is alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl, each of which may be optionally substituted.
  • Cyano or “carbonitrile” refers to the group -CN.
  • Cycloalkyl is a subset of “alkyl” and refers to a saturated or partially saturated cyclic group of from 3 to about 10 carbon atoms and no ring heteroatoms and having a single ring or multiple rings including fused, bridged, and spiro ring systems.
  • cycloalkyl applies when the point of attachment is at a non-aromatic carbon atom (e.g., 5,6,7,8,- tetrahydronaphthalene-5-yl).
  • cycloalkyl includes cycloalkenyl groups.
  • examples of cycloalkyl groups include, for instance, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and cyclohexenyl.
  • Haloalkyl refers to substitution of alkyl groups with 1 to 5 or, in some embodiments, 1 to 3 halo groups, e.g., -CH 2 C1, -CH 2 F, -CH 2 Br, -CFClBr, -CH 2 CH 2 C1, -CH 2 CH 2 F, -CF 3 , -CH 2 CF 3 , -CH 2 CC1 3 , and the like, and further includes those alkyl groups such as perfluoroalkyl in which all hydrogen atoms are replaced by fluorine atoms.
  • Haloaryl refers to aryl groups with one or more halo or halogen substituents.
  • haloaryl groups include phenyl groups in which from 1 to 5 hydrogens are replaced with a halogen.
  • Haloaryl groups include, for example, fluorophenyl, difluorophenyl,
  • Heteroalkyl refers to an alkyl group in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatom or heteroatomic group.
  • heteroalkyl may include 1, 2 or 3 heteroatomic groups, e.g. 1 heteroatomic group.
  • Heteroatoms include, but are not limited to, N, P, O, S, etc.
  • Heteroatomic groups include, but are not limited to, -NR-, -0-, -S-, -PH-, -P(0) 2 -, -S(O)-, - S(0) 2 -, and the like, where R is H, alkyl, aryl, cycloalkyl, heteroalkyl, heteroaryl or
  • heteroalkyl includes heterocycloalkyl (a cyclic heteroalkyl group), alkyl-heterocycloalkyl (a linear or branched aliphatic group attached to a cyclic heteroalkyl group), and the like.
  • Heteroalkyl groups include, but are not limited to, -OCH 3 , -CH 2 OCH 3 , - SCH 3 , -CH 2 SCH 3 , -NRCH 3 , -CH 2 NRCH 3 , and the like, where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl, each of which may be optionally substituted.
  • a heteroalkyl group comprises from 1 to about 10 carbon and hetero atoms, e.g., from 1 to 6 carbon and hetero atoms.
  • Heteroaryl refers to an aryl group in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatoms, as defined above.
  • heteroaryl may include 1, 2 or 3 heteroatomic groups, e.g. 1 heteroatomic group.
  • Heteroaryl groups include, but are not limited to, groups derived from acridine, benzoimidazole, benzothiophene, benzofuran, benzoxazole,
  • Heteroarylalkyl refers to an arylalkyl group in which one or more carbon atoms (and any associated hydrogen atoms) are independently replaced with the same or different heteroatoms, as defined above.
  • heteroarylalkyl may include 1, 2 or 3 heteroatomic groups.
  • Heteroarylalkyl groups include, but are not limited to, groups derived from heteroaryl groups with alkyl substituents (e.g. methylpyridine, dimethylisoxazole, etc.), hydrogenated heteroaryl groups (dihydroquinolines, e.g. 3,4-dihydroquinoline, dihydroisoquinolines, e.g.
  • a heteroarylalkyl group comprises from 6 to about 30 carbon and hetero atoms, for example from 6 to about 20 carbon and hetero atoms.
  • Heterocycloalkyl is a subset of “heteroalkyl” and refers to a saturated or unsaturated cycloalkyl group in which one or more carbon atoms (and any associated hydrogen atoms) are independently replaced with the same or different heteroatom. Heteroatoms include, but are not limited to, N, P, O, S, etc.
  • a heterocycloalkyl group may also contain a charged heteroatom or group, e.g., a quaternized ammonium group such as -N+(R)2- wherein R is alkyl, e.g., methyl, ethyl, etc.
  • Heterocycloalkyl groups include, but are not limited to, groups derived from epoxide, imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, piperidine, pyrrolidine, pyrrolidinone, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, quinuclidine, N-bromopyrrolidine, N-bromopiperidine, N-chloropyrrolidine, N-chloropiperidine, an N,N-dialkylpyrrolidinium, such as N,N-dimethylpyrrolidinium, a N,N-dialkylpiperidinium such as ⁇ , ⁇ -dimethylpiperidium, and the like.
  • the heterocycloalkyl group comprises from 3 to about 10 carbon and hetero atoms in the ring or rings. In some embodiments, heterocycloalkyl includes 1, 2 or 3 heteroatomic groups.
  • Hydrazino refers to the group -NHNH 2 .
  • Niro refers to the group -N0 2 .
  • Oxide refers to products resulting from the oxidation of one or more heteroatoms. Examples include N-oxides, sulfoxides, and sulfones.
  • solvate refers to an association or complex of one or more solvent molecules and a compound of the disclosure.
  • solvents that form solvates may include water, isopropanol, ethanol, methanol, dimethylsulfoxide, ethylacetate, acetic acid and ethanolamine.
  • hydrate refers to the complex formed by the combining of a compound described herein and water.
  • prodrug refers to compounds disclosed herein that include chemical groups which, in vivo, can be converted and/or can be split off from the remainder of the molecule to provide for the active drug, a pharmaceutically acceptable salt thereof, or a biologically active metabolite thereof.
  • Racemates refers to a mixture of enantiomers.
  • Stereoisomer or “stereoisomers” refer to compounds that differ in the chirality of one or more stereocenters. Stereoisomers include enantiomers and diastereomers. The compounds may exist in stereoisomeric form if they possess one or more asymmetric centers or a double bond with asymmetric substitution and, therefore, can be produced as individual stereoisomers or as mixtures. Unless otherwise indicated, the description is intended to include individual stereoisomers as well as mixtures. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see, e.g., Chapter 4 of Advanced Organic Chemistry, 4th ed., J. March, John Wiley and Sons, New York, 1992).
  • Substituted refers to a group wherein one or more hydrogens have been independently replaced with one or more substituents including, but not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, haloalkyl, heteroalkyl, heteroaryl,
  • aryl aryl-substituted aryl.
  • substituent when a group described above as being “optionally substituted” is substituted, that substituent is itself unsubstituted.
  • impermissible substitution patterns e.g., methyl substituted with 5 fluoro groups or heteroaryl groups having two adjacent oxygen ring atoms. Such impermissible substitution patterns are well known to the skilled artisan.
  • substituted When used to modify a chemical group, the term "substituted" may describe other chemical groups defined herein.
  • substituted aryl includes, but is not limted to, "arylalkyl.”
  • substituted groups will have 1 to 5 substituents, 1 to 3 substituents, 1 or 2 substituents or 1 substituent.
  • the optionally substituted groups of the invention may be unsubstituted.
  • Sulfonyl refers to the divalent group -S(0) 2 -.
  • Thiocyanate refers to the group -SCN.
  • Thiol refers to the group -SH.
  • “Pharmaceutically acceptable” refers to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.
  • “Pharmaceutically acceptable salt” refers to a salt of a compound that is pharmaceutically acceptable and that possesses (or can be converted to a form that possesses) the desired pharmacological activity of the parent compound.
  • Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, lactic acid, maleic acid, malonic acid, mandelic acid, methanesulfonic acid, 2-napththalenesulfonic acid, oleic acid, palmitic acid, propionic acid, stearic acid, succinic acid, tartaric acid, p-toluenesulfonic acid,
  • n is the number of hydrogen atoms in the molecule.
  • the deuterium atom is a non-radioactive isotope of the hydrogen atom.
  • Such compounds exhibit may increase resistance to metabolism, and thus may be useful for increasing the half-life of the compounds when administered to a mammal. See, e.g., Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol. Sci., 5(12):524-527 (1984).
  • Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogen atoms have been replaced by deuterium.
  • Filgotinib Filgotinib also known as GLPG0634, is described in U.S. Patent No. 8,563,545, and has the following structure:
  • the BET inhibitor is a compound of Formula (I):
  • one ⁇ is a single bond and the other— is a double bond
  • R la and R lb are each independently Ci_ 6 alkyl optionally substituted with from 1 to 5 R groups;
  • R 2a and R 2b are each independently H or halo
  • R 3 is -B(OH) 2 , -B(OR a ) 2 , halo, -C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a , -S(0) 2 NR a R b , Ci_ io alkyl, Ci_io alkoxy, amino, Cs_io aryl, C 6 -2o arylalkyl, Ci_io heteroalkyl, Cs_io heteroaryl, or C 6 -2o heteroarylalkyl, wherein each of Ci_io alkyl, Ci_io alkoxy, amino, C5-10 aryl, C 6 -20 arylalkyl, Ci-10 heteroalkyl, C5-10 heteroaryl, or C 6 -20 heteroarylalkyl is optionally substituted with from 1 to 5 R 20 groups; one of R 4a and R 4b is selected from the group consisting of H and Ci_ 6 alkyl optionally
  • R 5 is -C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a , or -S(0) 2 NR a R b , H, CMO alkyl, C O haloalkyl, Ci_io alkoxy, amino, C5 0 aryl, C 6 -2o arylalkyl, Ci_io heteroalkyl, Cs_io heteroaryl, or C 6 -2o heteroarylalkyl, wherein each of CMO alkyl, CMO haloalkyl, CMO alkoxy, amino, C5-10 aryl, C 6 -20 arylalkyl, C O heteroalkyl, C5-10 heteroaryl, and C 6 -20 heteroarylalkyl is optionally
  • each R a and R b is independently selected from the group consisting of H, C MO alkyl, Cs_io aryl, C 6 -20 arylalkyl, CMO heteroalkyl, C5-10 heteroaryl, and C 6 -20 heteroarylalkyl, each of which is
  • each R is independently selected from the group consisting of acyl, CMO alkyl, CMO alkoxy, amino, amido, amidino, Cs_io aryl, C 6 -2o arylalkyl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, CMO haloalkyl, CMO heteroalkyl, C5-10 heteroaryl, C 6 -20
  • heteroarylalkyl hydroxy, hydrazino, imino, oxo, nitro, sulfinyl, sulfonic acid, sulfonyl, thiocyanate, thiol, and thione, or a pharmaceutically acceptable salt thereof.
  • Compounds of Formula (I) can include, independently, one or more of the following features. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments.
  • R la and R lb are each independently Ci_6 alkyl.
  • R la and R lb are different, and in other compounds R la and R lb are the same.
  • R la and R lb are each independently a Ci_ 6 alkyl optionally substituted with 1-5 R 20 groups.
  • R la and R lb are both methyl.
  • one of R la and R lb is a methyl and the other is a methyl substituted with a hydroxy.
  • R la and R lb are both methyl substituted with a hydroxy. In some embodiments, one of R la and R lb is a methyl and the other is a methyl substituted with an amine. In some compounds, R la and R lb are both methyl substituted with an amine.
  • R and R are both H. In some embodiments, R and R are both halo. In some embodiments, one of R 2a and R 2b is H and the other is halo. In some embodiments, the halo is -F or -CI.
  • R 3 is -B(OH) 2 , -B(OR a ) 2 , or halo.
  • R 3 is - C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a , or -S(0) 2 NR a R b wherein R a and R b are described above.
  • R 3 is -C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a , or
  • R 3 is -C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a , or -S(0) 2 NR a R b , wherein each R a and R b is independently Cs_io aryl or Cs_io heteroaryl.
  • R 3 is selected from the group consisting of CM O alkyl, C M O alkoxy, amino, Cs_io aryl, C 6 -2o arylalkyl, Ci-io heteroalkyl, C5-10 heteroaryl, and C 6 -20 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R 20 groups, wherein R 20 is described above.
  • R J is C i-io alkyl, Ci_io alkoxy, or Ci_io heteroalkyl, each of which may be optionally substituted as described above.
  • the heteroalkyl is a heterocycloalkyl.
  • R is C6-20 arylalkyl or C6-20 heteroarylalkyl, each of which may be optionally substituted as described above.
  • R is C5-10 aryl, C6-20 arylalkyl, C5-10 heteroaryl, or C 6 -2o heteroarylalkyl, each of which may be optionally substituted as described above.
  • R is amino optionally substituted as described above.
  • R 3 is -NH 2
  • R 3 is -NR y R z , wherein R y and R z together with the nitrogen to which they are bonded form a CM O heteroalkyl or C5-10 heteroaryl, each of which may be optionally substituted as described above.
  • R include the following:
  • one of R a or R is H and the other is absent, that is, in some compounds R 4a is H and R 4b is absent, and in other compounds R 4a is absent and R 4b is H.
  • one of R 4a and R 4b is alkyl and the other is absent, that is, in some compounds R 4a is alkyl and R 4b is absent, and in other compounds R 4a is absent and R 4b is alkyl.
  • the alkyl is methyl.
  • R 5 is -C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a , or -S(0) 2 NR a R b , wherein R a and R b are described above.
  • R 5 is -C(0)OR a , -NHC(0)OR a , - NHS(0) 2 R a , or -S(0) 2 NR a R b , wherein each R a and R b is independently Ci -10 alkyl or C 5 _i 0 aryl, each of which may be optionally substituted as described above.
  • R 5 is -NHC(0)OR a , wherein R a is methyl.
  • R 5 is - NHS(0) 2 R a , wherein R a is Ci_io alkyl or Cs_io aryl, each of which may be optionally substituted as described above.
  • R 5 is -NHS(0) 2 R a , wherein R a is cyclopropyl.
  • R 5 is selected from the group consisting of H, CMO alkyl, Ci-io haloalkyl, CMO alkoxy, amino, C5-10 aryl, C 6 - 2 o arylalkyl, CMO heteroalkyl, C5-10 heteroaryl,
  • R is CMO alkyl optionally substituted as described above.
  • the CMO alkyl is a CMO cycloalkyl, e.g. cyclopropyl.
  • R 5 is amino optionally substituted as described above.
  • R 5 is -NH 2
  • R 5 is -NR y R z , wherein R y is H and R z is alkyl, e.g. cyclopropyl.
  • R 5 is alkoxy, e.g. methoxy.
  • R la , R lb , R 3 , R 4a , R 4b and R 5 are optionally substituted with from 1 to 5 (i.e. 1, 2, 3, 4 or 5) R 20 groups as described above. In some embodiments, R la , R lb , R 3 , R 4a , R 4b and R 5 are optionally substituted with 1, 2, or 3 R 20 groups. In some embodiments, each R 20 is independently selected from the group consisting of alkyl, alkoxy, amino, cyano, halo, haloalkyl, heteroalkyl, hydroxy, and sulfonyl.
  • each R 20 is independently selected from the group consisting of aryl, alkylaryl, heteroaryl, and heteroalkylaryl.
  • R la , R lb , R 3 , R 4a , R 4b and R 5 are not substituted. In some compounds, R 20 is not substituted.
  • — is a single bond or a double bond
  • R la and R lb are each independently Ci_ 6 alkyl optionally substituted with from 1 to 5 R 20 groups;
  • R 3 is boronic acid, boronic acid ester, halo, -C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a ,
  • R 5 is -C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a , or -S(0) 2 NR a R b , H, CM 0 alkyl, C 0 haloalkyl, Ci_io alkoxy, amino, Cs_io aryl, C 6 -2o arylalkyl, Ci_io heteroalkyl, Cs_io heteroaryl, or
  • each of Ci_io alkyl, Ci_io haloalkyl, Ci_io alkoxy, amino, C5-10 aryl, C 6 -20 arylalkyl, Ci_io heteroalkyl, Cs_io heteroaryl, and C 6 -2o heteroarylalkyl is optionally substituted with from 1 to 5 R 20 groups;
  • each R a and R b is independently selected from the group consisting of H, C M O alkyl, C5-10 aryl, C 6 -20 arylalkyl, CM O heteroalkyl, C5-10 heteroaryl, and C 6 -20 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R 20 groups;
  • each R 20 is independently selected from the group consisting of acyl, CM O alkyl, CM O alkoxy, amino, amido, amidino, C5-10 aryl, C6-20 arylalkyl, azido,
  • heteroarylalkyl hydroxy, hydrazino, imino, oxo, nitro, sulfinyl, sulfonic acid, sulfonyl, thiocyanate, thiol, and thione, or a pharmaceutically acceptable salt thereof.
  • R la and R lb are each independently C 1-6 alkyl optionally substituted with from 1 to 5 R groups;
  • R 3 is -B(OH) 2 , -B(OR a ) 2 , halo, -C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a , -S(0) 2 NR a R b , Ci_ io alkyl, Ci_io alkoxy, amino, Cs_io aryl, C 6 -2o arylalkyl, CMO heteroalkyl, Cs_io heteroaryl, or C 6 -2o heteroarylalkyl, wherein each of CMO alkyl, CMO alkoxy, amino, C5-10 aryl, C 6 -20 arylalkyl, CMO heteroalkyl, Cs_io heteroaryl, or C 6 -2o heteroarylalkyl is optionally substituted with from 1 to 5 R 20 groups;
  • R 5 is -C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a , or -S(0) 2 NR a R b , H, CMO alkyl, CMO haloalkyl, CMO alkoxy, amino, C5-10 aryl, C 6 -20 arylalkyl, CMO heteroalkyl, C5-10 heteroaryl, or C 6 -2o heteroarylalkyl, wherein each of CMO alkyl, CMO haloalkyl, CMO alkoxy, amino, Cs_io aryl, C 6 -2o arylalkyl, C O heteroalkyl, C5-10 heteroaryl, and C 6 -20 heteroarylalkyl is optionally
  • each R a and R b is independently selected from the group consisting of H, C MO alkyl, Cs_io aryl, C 6 -2o arylalkyl, CMO heteroalkyl, Cs_io heteroaryl, and C 6 -2o heteroarylalkyl, each of which is
  • each R is independently selected from the group consisting of acyl, CMO alkyl, CMO alkoxy, amino, amido, amidino, Cs_io aryl, C 6 -2o arylalkyl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, CMO haloalkyl, CMO heteroalkyl, Cs_io heteroaryl, C 6 -2o
  • heteroarylalkyl hydroxy, hydrazino, imino, oxo, nitro, sulfinyl, sulfonic acid, sulfonyl, thiocyanate, thiol, and thione, or a pharmaceutically acceptable salt thereof.
  • R la and R lb are each independently Ci_ 6 alkyl optionally substituted with from 1 to 5 R groups;
  • R 3 is -B(OH) 2 , -B(OR a ) 2 , halo, -C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a , -S(0) 2 NR a R b , Ci_ io alkyl, Ci_io alkoxy, amino, C5-10 aryl, C 6 -20 arylalkyl, CMO heteroalkyl, C5-10 heteroaryl, or C 6 -20 heteroarylalkyl, wherein each of Ci_io alkyl, Ci_io alkoxy, amino, Cs_io aryl, C 6 -2o arylalkyl, Ci_io heteroalkyl, C5-10 heteroaryl, or C6-20 heteroarylalkyl is optionally substituted with from 1 to 5 R 20 groups;
  • R 5 is -C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a , or -S(0) 2 NR a R b , H, Ci -10 alkyl, C 0 haloalkyl, Ci_io alkoxy, amino, C5 0 aryl, C 6 -2o arylalkyl, Ci_io heteroalkyl, Cs_io heteroaryl, or C 6 -2o heteroarylalkyl, wherein each of CM O alkyl, CM O haloalkyl, CM O alkoxy, amino, C5-10 aryl, C 6 -20 arylalkyl, C O heteroalkyl, C5-10 heteroaryl, and C 6 -20 heteroarylalkyl is optionally substituted with from 1 to 5 R 20 groups; each R a and R b is independently selected from the group consisting of H, C M O alkyl, Cs_io aryl, C 6 -20
  • R 3 is -B(OH) 2 , -B(OR a ) 2 , halo, -C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a , -S(0) 2 NR a R b , Ci_ 10 alkyl, Ci_io alkoxy, amino, Cs_io aryl, C 6 - 2 o arylalkyl, Ci_io heteroalkyl, Cs_io heteroaryl, or C 6 - 2 o heteroarylalkyl, wherein each of Ci_io alkyl, Ci_io alkoxy, amino, C5-10 aryl, C 6 - 2 o arylalkyl, Ci-10 heteroalkyl, C5-10 heteroaryl, or C 6 - 2 o heteroarylalkyl is optionally substituted with from 1 to 5 R 20 groups;
  • R 5 is -C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a , or -S(0) 2 NR a R b , H, Ci -10 alkyl, C 0 haloalkyl, Ci-10 alkoxy, amino, C5-10 aryl, C 6 - 2 o arylalkyl, Ci-10 heteroalkyl, C5-10 heteroaryl, or C 6 - 2 o heteroarylalkyl, wherein each of Ci_io alkyl, Ci_io haloalkyl, Ci_io alkoxy, amino, Cs_io aryl, C 6 - 2 o arylalkyl, CMO heteroalkyl, Cs_io heteroaryl, and C 6 - 2 o heteroarylalkyl is optionally
  • each R a and R b is independently selected from the group consisting of H, C MO alkyl, C5-10 aryl, C 6 - 2 o arylalkyl, CMO heteroalkyl, Cs_io heteroaryl, and C 6 - 2 o heteroarylalkyl, each of which is
  • each R is independently selected from the group consisting of acyl, CM O alkyl, CM O alkoxy, amino, amido, amidino, C5-10 aryl, C 6 -20 arylalkyl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, CM O haloalkyl, Ci_io heteroalkyl, Cs_io heteroaryl, C 6 -2o
  • heteroarylalkyl hydroxy, hydrazino, imino, oxo, nitro, sulfinyl, sulfonic acid, sulfonyl, thiocyanate, thiol, and thione, or a pharmaceutically acceptable salt thereof.
  • R 3 is -B(OH) 2 , -B(OR a ) 2 , halo, -C(0)OR a , -NHC(0)OR a , -NHS(0) 2 R a , -S(0) 2 NR a R b , Ci_
  • each R a and R b is independently selected from the group consisting of H, C M O alkyl, C5-10 aryl, C 6 -20 arylalkyl, CM O heteroalkyl, C5-10 heteroaryl, and C 6 -20 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R 20 groups; and each R 20 is independently selected from the group consisting of acyl, CM O alkoxy, amino, Cs_io aryl, C 6 -2o arylalkyl, CM O heteroalkyl, Cs_io heteroaryl, or C 6 -2o heteroarylalkyl, wherein each of C O alkyl, CM O alkoxy, amino, C5-10 aryl, C 6 -20 arylalkyl, CM O heteroalkyl, Cs_io heteroaryl, or C 6 -2o heteroarylalkyl is optionally substituted with from 1 to 5 R 20 groups; each R a and R b is
  • a separate embodiment comprises a compound of Formula le, as defined above, wherein R J is C i-io alkyl, CM O alkoxy, or CM O heteroalkyl, each of which may be optionally substituted with from 1 to 5 R 20 groups, or a pharmaceutically acceptable salt thereof.
  • the BET inhibitor is a compound selected from the table below, or a pharmaceutically acceptable salt thereof.
  • the BET inhibitor is (2-cyclopropyl-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol- 4-yl)di(pyrazin-2-yl)methanol, or a pharmaceutically acceptable salt thereof.
  • the BET inhibitor is (2-cyclopropyl-6-(3,5-dimethylisoxazol-4-yl)-lH- benzo[d]imidazol-4-yl)(pyridin-2-yl)(pyrimidin-5-yl)methanol, or a pharmaceutically acceptable salt thereof.
  • the BET inhibitor is (2-cyclopropyl-6-(3,5- dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-4-yl)(pyridin-2-yl)(pyrimidin-5-yl)methanol, or a pharmaceutically acceptable salt thereof.
  • the BET inhibitor is (2-cyclopropyl-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-4-yl)(pyridin-2- yl)(pyrimidin-2-yl)methanol, or a pharmaceutically acceptable salt thereof.
  • the BET inhibitor is (2-cyclopropyl-6-(3,5-dimethylisoxazol-4-yl)-lH- benzo[d]imidazol-4-yl)di(pyridin-3-yl)methanol, or a pharmaceutically acceptable salt thereof.
  • the BET inhibitor is (2-cyclopropyl-6-(3,5- dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-4-yl)(phenyl)(pyridin-2-yl)methanol, or a pharmaceutically acceptable salt thereof.
  • the BET inhibitor is (2-cyclopropyl-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-4- yl)(phenyl)(pyridin-3-yl)methanol, or a pharmaceutically acceptable salt thereof.
  • the BET inhibitor is 4-(2-cyclopropyl-7-(6-methylquinolin-5-yl)-lH- benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole or a pharmaceutically acceptable salt thereof.
  • the BET inhibitors described above may be prepared by methods disclosed in U.S. Patent Application Publication No. 2014/0336190.
  • Pharmaceutically acceptable salts, esters, stereoisomers, tautomers, prodrugs, solvates, and deuterated forms of the compounds disclosed herein may be used in the methods and compositions disclosed herein.
  • references to the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.”
  • the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise.
  • reference to “the compound” includes a plurality of such compounds, and reference to “the assay” includes reference to one or more assays and equivalents thereof known to those skilled in the art.
  • Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se.
  • the term “about X” thus includes description of "X”.
  • the term “about” includes the indicated amount + 10%.
  • the term “about” includes the indicated amount + 5%.
  • the term “about” includes the indicated amount + 1%.
  • Effective amount or “therapeutically effective amount” means the amount of a compound described herein that may be effective to elicit the desired biological or medical response. These terms include the amount of a compound that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease. The effective amount will vary depending on the compound, the disease and its severity and the age, weight, etc., of the subject to be treated.
  • Subject and “subjects” refers to humans, domestic animals (e.g., dogs and cats), farm animals (e.g., cattle, horses, sheep, goats and pigs), laboratory animals (e.g., mice, rats, hamsters, guinea pigs, pigs, rabbits, dogs, and monkeys), and the like.
  • domestic animals e.g., dogs and cats
  • farm animals e.g., cattle, horses, sheep, goats and pigs
  • laboratory animals e.g., mice, rats, hamsters, guinea pigs, pigs, rabbits, dogs, and monkeys
  • Treating" and “treatment” of a disease include the following: (1) preventing or reducing the risk of developing the disease, i.e., causing the clinical symptoms of the disease not to develop in a subject that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease,(2) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms, and (3) relieving the disease, i.e., causing regression of the disease or its clinical symptoms.
  • ex vivo means within a living individual, as within an animal or human. In this context, the methods described herein may be used therapeutically in an individual.
  • Ex vivo means outside of a living individual. Examples of ex vivo cell populations include in vitro cell cultures and biological samples including fluid or tissue samples obtained from individuals. Such samples may be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. In this context, the compounds and compositions described herein may be used for a variety of purposes, including therapeutic and experimental purposes.
  • the compounds and compositions described herein may be used ex vivo to determine the optimal schedule and/or dosing of administration of a compound of the present disclosure for a given indication, cell type, individual, and other parameters. Information gleaned from such use may be used for experimental purposes or in the clinic to set protocols for in vivo treatment. Other ex vivo uses for which the compounds and compositions described herein may be suited are described below or will become apparent to those skilled in the art.
  • the selected compounds may be further characterized to examine the safety or tolerance dosage in human or non-human subjects. Such properties may be examined using commonly known methods to those skilled in the art.
  • synergy and “synergistic effect” encompass a more than additive effect of two or more agents compared to their individual effects.
  • synergy or synergistic effect refers to an advantageous effect of using two or more agents in combination, e.g., in a pharmaceutical composition, or in a method of treatment.
  • a synergistic effect may be attained when the active ingredients are: (1) co-formulated and administered or delivered simultaneously in a combined formulation; (2) delivered by alternation or in parallel as separate formulations; or (3) by some other regimen. When delivered in alternation therapy, a synergistic effect may be attained when the compounds are administered or delivered sequentially, e.g.
  • the synergistic anti-cancer effect of the combination of filgotnib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, and a BET inhibitor is greater than the predicted purely additive effects of the individual compounds of the combination.
  • the present disclosure in one embodiment, provides a method for treating cancer in a human in need thereof, comprising administering to the human a therapeutically effective amount of filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, and a therapeutically effective amount of a BET inhibitor.
  • the methods comprising combination of filgotinib or a
  • the amount or dosage of filgotinib, or pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, the BET inhibitor, or both, used in combination does not exceed the level at which each agent is used individually, e.g., as a monotherapy.
  • the amount or dosage of filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, or the BET inhibitor, or both, used in combination is lower (e.g., at least 20%, at least 30%, at least 40%, or at least 50% lower) than the amount or dosage of each agent used individually, e.g., as a monotherapy.
  • the amount or dosage of filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, the BET inhibitor, or both, used in combination that results in treatment of cancer is lower (e.g., at least 20%, at least 30%, at least 40%, or at least 50% lower) than the amount or dosage of each agent used individually, e.g., as a monotherapy.
  • filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, is administered intravenously, intramuscularly, parenterally, nasally or orally.
  • the BET inhibitor is administered intravenously,
  • filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, is administered prior, after or concurrently with the BET inhibitor.
  • the present disclosure in one embodiment, provides a method for treating cancer in a human in need thereof, comprising administering to the human a therapeutically effective amount of filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, and a therapeutically effective amount of a BET inhibitor, wherein the BET inhibitor is a compound of the Formula (I) as disclosed herein, wherein the cancer is carcinoma, sarcoma, melanoma, lymphoma or leukemia.
  • this disclosure provides a method for treating cancer in a human in need thereof, comprising administering to the human:
  • the cancer is carcinoma, sarcoma, melanoma, lymphoma or leukemia.
  • filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof is administered intravenously, intramuscularly, parenterally, nasally or orally.
  • the compound in step (ii) is administered
  • filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof is administered prior, after or concurrently with compound in step (ii).
  • the cancer is carcinoma, sarcoma, melanoma, lymphoma or leukemia. In other embodiments, the cancer is a hematologic malignancy. In some embodiments, the cancer is carcinoma, sarcoma, melanoma, lymphoma or leukemia. In other embodiments, the cancer is a hematologic malignancy. In some embodiments, the cancer is a hematologic malignancy.
  • the cancer is leukemia ⁇ e.g. , chronic lymphocytic leukemia), lymphoma ⁇ e.g. , non- Hodgkin's lymphoma), or multiple myeloma.
  • the cancer is a solid tumor.
  • the cancer is small lymphocytic lymphoma, non-Hodgkin's lymphoma, indolent non-Hodgkin's lymphoma (iNHL), refractory iNHL, mantle cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, immunoblastic large cell lymphoma, lymphoblastic lymphoma, Splenic marginal zone B-cell lymphoma (+/- villous lymphocytes), nodal marginal zone lymphoma (+/- monocytoid B-cells), extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type, cutaneous T-cell lymphoma, extranodal T-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T- cell lymphoma, mycosis fungoides, B-cell lymphoma, diffuse large B-
  • the cancer is pancreatic cancer, urological cancer, bladder cancer, colorectal cancer, colon cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, thyroid cancer, gall bladder cancer, lung cancer (e.g. non-small cell lung cancer, small- cell lung cancer), ovarian cancer, cervical cancer, gastric cancer, endometrial cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain tumors (e.g.
  • glioma anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma
  • bone cancer soft tissue sarcoma, retinoblastomas, neuroblastomas, peritoneal effusions, malignant pleural effusions, mesotheliomas, Wilms tumors, trophoblastic neoplasms, hemangiopericytomas, Kaposi's sarcomas, myxoid carcinoma, round cell carcinoma, squamous cell carcinomas, esophageal squamous cell carcinomas, oral carcinomas, cancers of the adrenal cortex, or ACTH-producing tumors.
  • the human in need thereof may be an individual who has or is suspected of having a cancer.
  • the human is at risk of developing a cancer (e.g., a human who is genetically or otherwise predisposed to developing a cancer) and who has or has not been diagnosed with the cancer.
  • an "at risk" subject is a subject who is at risk of developing cancer (e.g., a hematologic malignancy).
  • the subject may or may not have detectable disease, and may or may not have displayed detectable disease prior to the treatment methods described herein.
  • An at risk subject may have one or more so-called risk factors, which are measurable parameters that correlate with development of cancer, such as described herein.
  • a subject having one or more of these risk factors has a higher probability of developing cancer than an individual without these risk factor(s).
  • These risk factors may include, for example, age, sex, race, diet, history of previous disease, presence of precursor disease, genetic (e.g. , hereditary) considerations, and
  • a human at risk for cancer includes, for example, a human whose relatives have experienced this disease, and those whose risk is determined by analysis of genetic or biochemical markers. Prior history of having cancer may also be a risk factor for instances of cancer recurrence.
  • provided herein is a method for treating a human who exhibits one or more symptoms associated with cancer (e.g., a hematologic malignancy).
  • a human who exhibits one or more symptoms associated with cancer e.g., a hematologic malignancy.
  • the human is at an early stage of cancer. In other embodiments, the human is at an advanced stage of cancer.
  • provided herein is a method for treating a human who is undergoing one or more standard therapies for treating cancer (e.g., a hematologic malignancy), such as chemotherapy, radiotherapy, immunotherapy, and/or surgery.
  • cancer e.g., a hematologic malignancy
  • the combination of filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, and a BET inhibitor may be administered before, during, or after administration of chemotherapy, radiotherapy, immunotherapy, and/or surgery.
  • a method for treating a human who is "refractory” to a cancer treatment or who is in "relapse” after treatment for cancer e.g., a hematologic malignancy.
  • a subject "refractory" to an anti-cancer therapy means they do not respond to the particular treatment, also referred to as resistant.
  • the cancer may be resistant to treatment from the beginning of treatment, or may become resistant during the course of treatment, for example after the treatment has shown some effect on the cancer, but not enough to be considered a remission or partial remission.
  • a subject in "relapse” means that the cancer has returned or the signs and symptoms of cancer have returned after a period of improvement, e.g. after a treatment has shown effective reduction in the cancer, such as after a subject is in remission or partial remission.
  • the human is (i) refractory to at least one anti-cancer therapy, or (ii) in relapse after treatment with at least one anti-cancer therapy, or both (i) and (ii). In some of embodiments, the human is refractory to at least two, at least three, or at least four anti-cancer therapies (including, for example, standard or experimental chemotherapies).
  • a human who is sensitized is a human who is responsive to the treatment involving administration of filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, in combination with a BET inhibitor or who has not developed resistance to such treatment.
  • rituximab (Rituxan®)
  • rituximab (Rituxan ®) combined with fludarabine (sometimes abbreviated as FR);
  • cyclophosphamide (Cytoxan®) combined with fludarabine; cyclophosphamide combined with rituximab and fludarabine (sometimes abbreviated as FCR); cyclophosphamide combined with vincristine and prednisone (sometimes abbreviated as
  • cyclophosphamide doxorubicin
  • vincristine Oncovin
  • prednisone sometimes referred to as CHOP
  • Chlorambucil combined with prednisone, rituximab, obinutuzumab, or ofatumumab pentostatin combined with cyclophosphamide and rituximab (sometimes abbreviated as PCR); bendamustine (Treanda®) combined with rituximab ((sometimes abbreviated as BR); alemtuzumab (Campath®);
  • a method for treating a human for a cancer, with comorbidity wherein the treatment is also effective in treating the comorbidity.
  • cancer to cancer is a disease that occurs at the same time as the cancer.
  • compositions comprising filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, and compositions comprising a BET inhibitor can be prepared and placed in an appropriate container, and labeled for treatment of an indicated condition. Accordingly, provided is also an article of manufacture, such as a container comprising a unit dosage form of filgotinib, or a
  • the article of manufacture is a container comprising (i) a unit dosage form of filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, and one or more pharmaceutically acceptable carriers, adjuvants or excipients; and (ii) a unit dosage form of a BET inhibitor, and one or more pharmaceutically acceptable carriers, adjuvants or excipients.
  • the unit dosage form for both filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, and the BET inhibitor is a tablet.
  • kits also are contemplated.
  • a kit can comprise unit dosage forms of filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, and compositions comprising a BET inhibitor, and a package insert containing instructions for use of the composition in treatment of a medical condition.
  • the kits comprises (i) a unit dosage form of filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, and one or more pharmaceutically acceptable carriers, adjuvants or excipients; and (ii) a unit dosage form of a BET inhibitor, and one or more pharmaceutically acceptable carriers, adjuvants or excipients.
  • the unit dosage form for both filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, and the BET inhibitor is a tablet.
  • kits comprising (i) a pharmaceutical composition comprising filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof; (ii) a pharmaceutical composition comprising a BET inhibitor; and (iii) instructions for use of filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof and the BET inhibitor in treating cancer.
  • this disclosure provides a kit comprising:
  • composition comprising filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof;
  • composition comprising:
  • this disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, and BET inhibitor, and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition exhibits synergy in treating cancer.
  • this disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof and a BET inhibitor, such as a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a BET inhibitor such as a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • composition exhibits synergy in treating cancer.
  • this disclosure provides a co-formulation comprising filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof; a BET inhibitor; and a pharmaceutically acceptable carrier.
  • the co-formulation exhibits synergy in treating cancer.
  • this disclosure provides a co-formulation comprising filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof; and a therapeutically effective amount of a BET inhibitor, such as a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
  • a BET inhibitor such as a compound of Formula (I) or a pharmaceutically acceptable salt thereof
  • the co-formulation exhibits synergy in treating cancer.
  • this disclosure provides a co-formulation comprising:
  • this disclosure provides combination therapy for treating cancer, wherein separate compositions comprising filgotnib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, and a BET inhibitor are used.
  • a composition comprising filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof and a composition comprising a BET inhibitor, such as a compound of Formula (I) or a pharmaceutically acceptable salt thereof are used separately for the combination therapy.
  • compositions and/or co-formulations may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, for example as described in those patents and patent applications incorporated by reference, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as an inhalant, or via an impregnated or coated device such as a stent, for example, or an artery- inserted cylindrical polymer.
  • the compounds described herein may be administered orally.
  • Oral administration may be via, for example, capsule or enteric coated tablets.
  • the active ingredient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container.
  • a carrier that can be in the form of a capsule, sachet, paper or other container.
  • the excipient serves as a diluent, it can be in the form of a solid, semi- solid, or liquid material (as above), which acts as a vehicle, carrier or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents;
  • compositions can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the subject by employing procedures known in the art.
  • Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations.
  • Another formulation for use in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts.
  • the construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
  • the dosing regimen of filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, and a BET inhibiting compound disclosed herein (e.g. a compound of Formula (I) or a pharmaceutically acceptable salt thereof) in the methods provided herein may vary depending upon the indication, route of administration, and severity of the condition. For instance, depending on the route of administration, a suitable dose can be calculated according to body weight, body surface area, or organ size. The final dosing regimen is determined by the attending physician in view of good medical practice, considering various factors that modify the action of drugs, e.g.
  • the specific activity of the compound includes time and frequency of administration, drug combinations, reaction sensitivities, and tolerance/response to therapy. Further refinement of the doses appropriate for treatment involving any of the formulations mentioned herein is done routinely by the skilled practitioner without undue experimentation, especially in light of the dosing information and assays disclosed, as well as the pharmacokinetic data observed in human clinical trials.
  • Appropriate doses can be ascertained through use of established assays for determining concentration of the agent in a body fluid or other sample together with dose response data.
  • the dose and frequency of dosing may depend on pharmacokinetic and pharmacodynamic, as well as toxicity and therapeutic efficiency data.
  • pharmacokinetic and pharmacodynamic information about filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof; and the BET inhibiting compounds disclosed herein e.g. a compound of Formula (I) or a pharmaceutically acceptable salt thereof
  • a therapeutically effective dose can be estimated initially from biochemical and/or cell-based assays.
  • the dosage can then be formulated in animal models to achieve a desirable circulating concentration range that modulates BET activity.
  • Toxicity and therapeutic efficacy of filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, or a compound of Formula (I) or a pharmaceutically acceptable salt thereof can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the "therapeutic index", which typically is expressed as the ratio LD 50 /ED 50 .
  • Compounds that exhibit large therapeutic indices, i.e., the toxic dose is substantially higher than the effective dose, are preferred.
  • the data obtained from such cell culture assays and additional animal studies can be used in formulating a range of dosage for human use.
  • the doses of such compounds lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
  • the formulation, route of administration, dosage and dosing frequency of filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, or a compound of Formula (I) or a pharmaceutically acceptable salt thereof may be based on one or more factors disclosed herein, and tailored to the individual subject, the nature of the condition to be treated in the subject, and generally, the judgment of the attending practitioner.
  • a therapeutically effective amount or a pharmaceutically effective amount refers to an amount that is sufficient to effect treatment, when administered to a subject (e.g. , a human) in need of such treatment.
  • a therapeutically effective amount of filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof is an amount sufficient to modulate JAK expression, and thereby treat a human suffering an indication, or to ameliorate or alleviate the existing symptoms of the indication.
  • pharmaceutically acceptable salt thereof is an amount sufficient to modulate activity of bromodomain-containing proteins, and thereby treat a human suffering an indication, or to ameliorate or alleviate the existing symptoms of the indication.
  • the therapeutically effective amount of any of the compounds disclosed herein may be determined based on data obtained from assays known in the art, including for example, an apoptosis assay.
  • dose refers to the total amount of an active ingredient (e.g. , filgotinib or a
  • the dose administered of any of the compounds disclosed herein may be administered once daily (QD), twice daily (BID), three times daily, four times daily, or more than four times daily using any suitable mode described herein (e.g. , oral administration). In some embodiments, the dose of any of the compounds disclosed herein is administered once daily. In some embodiments, the dose of any of the compounds disclosed herein is administered twice daily.
  • administration or treatment with the compounds disclosed herein may be continued for a number of days; for example, treatment may continue for at least 7 days, 14 days, or 28 days, for one cycle of treatment.
  • Treatment cycles are well known, and are frequently alternated with resting periods of about 1 to 28 days, commonly about 7 days or about 14 days, between cycles.
  • the treatment cycles in other embodiments, may also be continuous.
  • filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof is administered to a human at a dose between 40 mg and 1200 mg, between 40 mg and 800 mg, between 40 mg and 600 mg, or between 40 mg and 400 mg.
  • the therapeutically effective amount of filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof is administered to a human at a dose of from about 1 mg to about 200 mg, about 10 mg to about 200 mg, about 100 mg to about 200 mg, about 50 mg to about 175 mg, about 50 mg to about 200 mg, about 20 mg to about 160 mg, about 20 mg to about 150 mg, about 10 mg to about 100 mg, or about 75 mg to about 100 mg.
  • filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof is administered to a human at a dose between about 50 mg to about 200 mg.
  • filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof is administered to a human subject once, twice, three times, or four times daily. In some embodiments, about 50-200 mg of filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, is administered to a human subject once, twice, three times, or four times daily. In some embodiments, about 50-200 mg of filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, is administered to a human subject once daily.
  • exemplary doses of the BET inhibitor, such as a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for a human subject may be from about 0.1 mg to about 200 mg per day. In some embodiments, about 0.2 mg, about 1 mg, about 5 mg, about 10 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 180 mg, about 190 mg, about 200 mg. In some embodiments, the BET inhibitor, such as a compound of Formula (I) or a pharmaceutically acceptable salt thereof, is administered to a human at a dose between about 0.1 mg to about 50 mg.
  • the BET inhibitor such as a compound of Formula (I) or a pharmaceutically acceptable salt thereof, is administered to a human subject once, twice, three times, or four times daily. In some embodiments, about 0.2 mg, about 1 mg, about 10 mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg of the BET inhibitor, such as a compound of Formula (I) or a pharmaceutically acceptable salt thereof, is administered to a human subject once, twice, three times, or four times daily. In some embodiments, about 25 mg of the BET inhibitor, such as a compound of Formula (I) or a pharmaceutically acceptable salt thereof, is administered to a human subject once daily. In some embodiments, about 25 mg of the BET inhibitor:
  • compositions may, in some embodiments, be formulated in a unit dosage form.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient (e.g. , a tablet, capsule, ampoule).
  • the compounds are generally administered in a pharmaceutically effective amount.
  • each dosage unit contains from about 0.1 mg to about 200 mg of a compound disclosed herein, for example about 0.2 mg, about 1 mg, about 10 mg, about 50 mg, about 75 mg, about 100 mg, about 150 mg or about 200 mg.
  • each dosage unit contains from 0.1 to 200 mg of a compound disclosed herein. It will be understood, however, that the amount of the compound actually administered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual subject, and the severity of the subject's symptoms.
  • the principal active ingredient may be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of Formula (I), or a pharmaceutically acceptable salt thereof or filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof.
  • a pharmaceutical excipient for preparing solid compositions such as tablets, the principal active ingredient may be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of Formula (I), or a pharmaceutically acceptable salt thereof or filgotinib, or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof.
  • the active ingredient may be dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • the tablets or pills of the compounds disclosed herein may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer that serves to resist
  • filgotinib or a pharmaceutically acceptable salt, solvate, polymorph, or metabolite thereof, is formulated as a capsule or a tablet.
  • the capsule or tablet comprises about 10 mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, or about 500 mg of filgotinib. In certain embodiments, the capsule or tablet comprises from about 50 mg to about 200 mg of filgotinib. In certain embodiments, the capsule or tablet comprises about 50 mg, about 100 mg, about 125 mg or about 200 mg of filgotinib.
  • the BET inhibitor (e.g. a compound of Formula (I), or a pharmaceutically acceptable salt thereof) is formulated as a capsule or a tablet.
  • the capsule or tablet comprises about 0.2 mg, about 1 mg, about 5 mg, about 10 mg, about 25 mg, about 50 mg, about 75 mg or about 100 mg of the BET inhibitor.
  • the capsule or tablet comprises from about 0.2 mg to about 50 mg of the BET inhibitor.
  • the capsule or tablet comprises about 0.2 mg, about 1 mg, about 10 mg, about 25 mg or about 50 mg of the BET inhibitor.
  • the BET inhibitor: or a pharmaceutically acceptable salt thereof is formulated as a capsule or a tablet.
  • the capsule or tablet comprises about 0.1 mg, 0.2 mg, about 0.5 mg, about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 75 mg or about 100 mg of the BET inhibitor.
  • the capsule or tablet comprises from about 0.1 mg to about 50 mg of the BET inhibitor.
  • the capsule or tablet comprises about 0.2 mg, about 1 mg, about 10 mg or about 25 mg of the BET inhibitor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des méthodes et des compositions pharmaceutiques pour le traitement du cancer comprenant du filgotinib et un inhibiteur BET.
PCT/US2016/067039 2015-12-17 2016-12-15 Combinaison d'un inhibiteur de jak et d'un inhibiteur de bromodomaine pour le traitement de cancers WO2017106568A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562269075P 2015-12-17 2015-12-17
US62/269,075 2015-12-17

Publications (1)

Publication Number Publication Date
WO2017106568A1 true WO2017106568A1 (fr) 2017-06-22

Family

ID=57777703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/067039 WO2017106568A1 (fr) 2015-12-17 2016-12-15 Combinaison d'un inhibiteur de jak et d'un inhibiteur de bromodomaine pour le traitement de cancers

Country Status (1)

Country Link
WO (1) WO2017106568A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109928979A (zh) * 2017-12-15 2019-06-25 四川科伦博泰生物医药股份有限公司 吲哚酮类衍生物及其制备方法和用途
US10696666B2 (en) 2016-10-18 2020-06-30 CellCentric Limited Pharmaceutical compounds
WO2020257644A1 (fr) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Méthodes de traitement de troubles myéloprolifératifs
WO2020256739A1 (fr) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Procédés de traitement de troubles myéloprolifératifs
WO2021091535A1 (fr) 2019-11-05 2021-05-14 Constellation Pharmaceuticals, Inc. Traitement de troubles myéloprolifératifs avec cpi-0610 et inhibiteur de jak
US20220016165A1 (en) * 2020-02-20 2022-01-20 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
CN114369097A (zh) * 2020-10-15 2022-04-19 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
US11453662B2 (en) 2018-04-18 2022-09-27 Cellcentric Ltd Process for preparing modulators of p300 and/or CBP

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100331319A1 (en) * 2009-06-26 2010-12-30 Christel Jeanne Marie Menet Novel compound useful for the treatment of degenerative and inflammatory diseases
US20140336190A1 (en) 2013-05-09 2014-11-13 Gilead Sciences, Inc. Benzimidazole derivatives as bromodomain inhibitors
WO2015117981A1 (fr) 2014-02-07 2015-08-13 Galapagos Nv Nouveaux sels et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
US9284311B2 (en) 2012-06-22 2016-03-15 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100331319A1 (en) * 2009-06-26 2010-12-30 Christel Jeanne Marie Menet Novel compound useful for the treatment of degenerative and inflammatory diseases
US8563545B2 (en) 2009-06-26 2013-10-22 Galapagos Nv Compound useful for the treatment of degenerative and inflammatory diseases
US9284311B2 (en) 2012-06-22 2016-03-15 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
US20140336190A1 (en) 2013-05-09 2014-11-13 Gilead Sciences, Inc. Benzimidazole derivatives as bromodomain inhibitors
WO2015117981A1 (fr) 2014-02-07 2015-08-13 Galapagos Nv Nouveaux sels et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT, WILLIAMS & WILKINS, pages: 732
FOSTER: "Deuterium Isotope Effects in Studies of Drug Metabolism", TRENDS PHARMACOL. SCI., vol. 5, no. 12, 1984, pages 524 - 527, XP025943358, DOI: doi:10.1016/0165-6147(84)90534-0
J. MARCH: "Advanced Organic Chemistry", 1992, JOHN WILEY AND SONS
JAMIE BATES ET AL: "Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines", 58TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, vol. 128, 1 December 2016 (2016-12-01), pages 5104, XP055349798 *
JAMIE BATES ET AL: "The Combination of a BET Inhibitor (GS-5829) and a BTK Inhibitor (GS-4059) Potentiates DLBCL Cell Line Cell Death and Reduces Expression of MYC, IL-10, and IL-6 in Vitro", 58TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, vol. 128, 1 December 2016 (2016-12-01), pages 5116, XP055349804 *
S.M. BERGE ET AL., J. PHARMA SCI., vol. 66, no. 1, 1977, pages 1 - 19
VALENTA JOHN A ET AL: "Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells", vol. 122, no. 21, 1 November 2013 (2013-11-01), XP008181343, ISSN: 0006-4971, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/122/21/2842> *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10696666B2 (en) 2016-10-18 2020-06-30 CellCentric Limited Pharmaceutical compounds
US11377443B2 (en) 2016-10-18 2022-07-05 CellCentric Limited Pharmaceutical compounds
CN109928979A (zh) * 2017-12-15 2019-06-25 四川科伦博泰生物医药股份有限公司 吲哚酮类衍生物及其制备方法和用途
CN109928979B (zh) * 2017-12-15 2021-08-06 四川科伦博泰生物医药股份有限公司 吲哚酮类衍生物及其制备方法和用途
US11453662B2 (en) 2018-04-18 2022-09-27 Cellcentric Ltd Process for preparing modulators of p300 and/or CBP
WO2020257644A1 (fr) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Méthodes de traitement de troubles myéloprolifératifs
WO2020256739A1 (fr) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Procédés de traitement de troubles myéloprolifératifs
WO2021091535A1 (fr) 2019-11-05 2021-05-14 Constellation Pharmaceuticals, Inc. Traitement de troubles myéloprolifératifs avec cpi-0610 et inhibiteur de jak
US20220016165A1 (en) * 2020-02-20 2022-01-20 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
CN114369097A (zh) * 2020-10-15 2022-04-19 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
WO2022078356A1 (fr) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 Inhibiteur d'ahr hétéroaromatique

Similar Documents

Publication Publication Date Title
WO2017106568A1 (fr) Combinaison d&#39;un inhibiteur de jak et d&#39;un inhibiteur de bromodomaine pour le traitement de cancers
AU2017289158B2 (en) 4,6-diaminoquinazolines as Cot modulators and methods of use thereof
JP6919977B2 (ja) メニン−ｍｌｌの置換された阻害剤及びその使用方法
US10786480B2 (en) Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof
JP7000333B2 (ja) メニン－ｍｌｌの架橋された二環式阻害剤及びその使用方法
AU2017232610B2 (en) Compounds and methods for kinase modulation and indications therefore
AU2016367147B2 (en) Compounds and methods for kinase modulation, and indications therefor
JP6789239B2 (ja) Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
TW201920170A (zh) 經取代之menin-mll 抑制劑及使用方法
AU2019203122A1 (en) Cot modulators and methods of use thereof
JP6162130B2 (ja) Ｉｉｉ型受容体チロシンキナーゼの調節因子としての複素環式化合物及びその使用
JP2017527547A (ja) 癌を処置するための併用療法
EA035141B1 (ru) Способы и композиции для ингибирования взаимодействия менина с белками mll
WO2016145045A1 (fr) Compositions s&#39;utilisant dans le traitement du glioblastome
TW201444838A (zh) 吡啶並嘧啶類衍生物、其製備方法及其在醫藥上的應用
JP2013529652A (ja) 複素環アルキニルベンゼン化合物と、その医療用組成物および使用
EP3004088A1 (fr) Inhibiteurs du transporteur slc2a
EP4233859A1 (fr) Inhibiteurs de réseaux de kinase et leurs utilisations
TW202108572A (zh) Ｃｄｋ抑制劑
TW201722421A (zh) 雙脫水半乳糖醇或其衍生物和類似物藉由ｄｎａ損傷之誘導和細胞周期之延宕治療非小細胞肺癌、神經膠母細胞瘤及卵巢癌之用途
CN117715905A (zh) 检查点激酶1（chk1）抑制剂及其用途
JP6586463B2 (ja) ＰＩ３Ｋβ阻害剤としての複素環連結イミダゾピリダジン誘導体
WO2022245776A1 (fr) Inhibiteurs anti-cdk pour le traitement du cancer
Hossain et al. FDA-approved heterocyclic molecules for cancer treatment: Synthesis, dosage, mechanism of action and their adverse effect
JP2023513016A (ja) Ｎｅｋ２阻害剤としてのアミノピリミジニルアミノベンゾニトリル誘導体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16825623

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16825623

Country of ref document: EP

Kind code of ref document: A1